{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:44:06Z","timestamp":1792701846299,"version":"4.5.0"},"reference-count":41,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10659","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T05:06:35Z","timestamp":1630040795000},"source":"Crossref","is-referenced-by-count":9,"title":["Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study"],"prefix":"10.3892","volume":"22","author":[{"given":"Bogdan","family":"Patrichi","sequence":"first","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"\u0162\u0103poi","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Rogojin\u0103","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bedreag\u0103","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Dumitrache","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Itu","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Dragomir","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela-Georgiana","family":"Buciuc","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, \u2018Prof. Dr. Alexandru Obregia\u2019 Clinical Psychiatry Hospital, 041914 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"key20211014132412_b1-etm-0-0-10659"},{"key":"key20211014132412_b2-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4088\/jcp.v68n1115","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update","volume":"68","author":"Moore","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key20211014132412_b3-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs. monotherapy in schizophrenia: A meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr Bull"},{"key":"key20211014132412_b4-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs. first generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"key20211014132412_b5-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"key20211014132412_b6-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1600-0447.2010.01553.x","article-title":"Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients","volume":"122","author":"Baandrup","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"key20211014132412_b7-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a006928","article-title":"Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy","volume":"28","author":"Clark","year":"2002","journal-title":"Schizophr Bull"},{"key":"key20211014132412_b8-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.4088\/jcp.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000","volume":"65","author":"Ganguly","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"key20211014132412_b9-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/0269881103017002012","article-title":"Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients","volume":"17","author":"Paton","year":"2003","journal-title":"J Psychopharmacol"},{"key":"key20211014132412_b10-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ajp.2018.03.012","article-title":"Prevalence and correlates of antipsychotic polypharmacy in Hong Kong","volume":"33","author":"Lung","year":"2018","journal-title":"Asian J Psychiatr"},{"key":"key20211014132412_b11-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00127-012-0586-6","article-title":"Description of long-term polypharmacy among schizophrenia outpatients","volume":"48","author":"Suokas","year":"2013","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"key20211014132412_b12-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/pds.2083","article-title":"Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy","volume":"20","author":"Santone","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20211014132412_b13-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs. monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"key20211014132412_b14-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1017\/S1461145712000399","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"17","author":"Fleischhacker","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"key20211014132412_b15-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/ijnp\/pyz068","article-title":"Antipsychotic polypharmacy: A dirty little secret or a fashion?","volume":"23","author":"Lin","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"key20211014132412_b16-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr Res"},{"key":"key20211014132412_b17-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"25","DOI":"10.47162\/RJME.61.1.03","article-title":"Genetic aspects in schizophrenia. Receptoral theories. Metabolic theories","volume":"61","author":"Trifu","year":"2020","journal-title":"Rom J Morphol Embryol"},{"key":"key20211014132412_b18-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1192\/bjp.188.2.122","article-title":"Schizophrenia, neuroleptic medication and mortality","volume":"188","author":"Joukamaa","year":"2006","journal-title":"Br J Psychiatry"},{"key":"key20211014132412_b19-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"key20211014132412_b20-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4088\/JCP.08m04818yel","article-title":"Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: A population-based nested case-control study","volume":"71","author":"Baandrup","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"key20211014132412_b21-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.pnpbp.2005.06.009","article-title":"Patterns of clinical use of antipsychotics in hospitalized psychiatric patients","volume":"29","author":"Mauri","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20211014132412_b22-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","article-title":"Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study","volume":"58","author":"Sim","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"key20211014132412_b23-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.clinthera.2007.01.002","article-title":"Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a multisite Medicaid population, 1998-2003","volume":"29","author":"Morrato","year":"2007","journal-title":"Clin Ther"},{"key":"key20211014132412_b24-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1176\/appi.ps.54.1.55","article-title":"Combination antipsychotic therapy in clinical practice","volume":"54","author":"Tapp","year":"2003","journal-title":"Psychiatr Serv"},{"key":"key20211014132412_b25-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.pnpbp.2003.11.006","article-title":"A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second generation agent on patients with chronic schizophrenia","volume":"28","author":"Suzuki","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20211014132412_b26-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.schres.2017.05.015","article-title":"Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: Results from a nationwide cohort study","volume":"192","author":"Malandain","year":"2018","journal-title":"Schizophr Res"},{"key":"key20211014132412_b27-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1192\/bjp.187.3.243","article-title":"Polypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription","volume":"187","author":"Ito","year":"2005","journal-title":"Br J Psychiatry"},{"key":"key20211014132412_b28-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia: Benefits and risks","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"key":"key20211014132412_b29-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.rpsm.2013.01.001","article-title":"Emerging guidelines for the use of antipsychotic polypharmacy","volume":"6","author":"Stahl","year":"2013","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"key20211014132412_b30-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3892\/etm.2020.8974","article-title":"Aggressive behavior in psychiatric patients in relation to hormonal imbalance (Review)","volume":"20","author":"Trifu","year":"2020","journal-title":"Exp Ther Med"},{"key":"key20211014132412_b31-etm-0-0-10659"},{"key":"key20211014132412_b32-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pds.783","article-title":"Antipsychotic medication coprescribing in a large state hospital system","volume":"12","author":"Jaffe","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20211014132412_b33-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/WNF.0b013e31815cba78","article-title":"Antipsychotic Polypharmacy in Patients With Schizophrenia in a Brief Hospitalization Unit","volume":"31","author":"Lerma-Carrillo","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"key20211014132412_b34-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1177\/070674370104600404","article-title":"Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution","volume":"46","author":"Procyshyn","year":"2001","journal-title":"Can J Psychiatry"},{"key":"key20211014132412_b35-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"N Engl J Med"},{"key":"key20211014132412_b36-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/01.pra.0000341890.05383.45","article-title":"Polypharmacy with second-generation antipsychotics: A review of evidence","volume":"14","author":"Pandurangi","year":"2008","journal-title":"J Psychiatr Pract"},{"key":"key20211014132412_b37-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/0269881108089593","article-title":"Efficacy and tolerability of ziprasidone vs. risperidone as augmentation in patients partially responsive to clozapine: A randomised controlled clinical trial","volume":"23","author":"Zink","year":"2009","journal-title":"J Psychopharmacol"},{"key":"key20211014132412_b38-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key20211014132412_b39-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2006.12.030","article-title":"Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial","volume":"92","author":"Freudenreich","year":"2007","journal-title":"Schizophr Res"},{"key":"key20211014132412_b40-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry"},{"key":"key20211014132412_b41-etm-0-0-10659","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T08:54:00Z","timestamp":1634201640000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,8,27]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10659","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"article-number":"1225"}}